reserpine (serpasil) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Reserpine is an alkaloid, isolated from the Rauwolfia serpentina plant and developed by Ciba pharma. Reserpine was approved by FDA for the treatment of hypertension and psychotic disorders. The drug exerts its effect by blocking two vesicular monoamine transporters, VMAT1 and VMAT2. The blockade results in vesicles that lose their ability to store neurotransmitter molecules. Neurotransmitters, thus retained in cytosol, are then neutralized by MAO.   NCATS

Chemistry

  • SMILES: CO[C@H]1[C@@H](C[C@@H]2CN3CCC4=C(NC5=C4C=CC(OC)=C5)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)C6=CC(OC)=C(OC)C(OC)=C6
  • InChIKey: QEVHRUUCFGRFIF-MDEJGZGSSA-N
  • Mol. Mass: 608.6787
  • ALogP: 4.17
  • ChEMBL Molecules:
    rauwolfia serpentina  
    reserpine  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Discontinued
  • Delivery Methods: Oral
  • Pro Drug: No

Combination drugs

( chlorthalidone (Hygroton), reserpine (serpasil) - other name: regroton )
|
( reserpine (serpasil), chlorothiazide (diuril) - other name: chlorothiazide-reserpine )
|
( methyclothiazide (enduron), reserpine (serpasil) )
|
( quinethazone (hydromox), reserpine (serpasil) )
|
( reserpine (serpasil), trichlormethiazide (naqua) )
|
( polythiazide (renese), reserpine (serpasil) )
|
( reserpine (serpasil), hydroflumethiazide (saluron) - other name: salutensin )
|
( hydralazine (apresoline), hydrochlorothiazide (esidrix), reserpine (serpasil) - other names: cam-ap-es, hydralazine, hydrochlorothiazide w/ reserpine, hydrap-es )
|
( hydralazine (apresoline), reserpine (serpasil) - other name: dralserp )
|
( hydrochlorothiazide (esidrix), reserpine (serpasil) - other names: h.r, hydropres, hydro-reserp, reserpine and hydrochlorothiazide )

Alternative names

3,4,5-trimethoxybenzoyl methyl reserpate | (3beta,16beta,17alpha,18beta,20alpha)-11,17-dimethoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]yohimban-16-carboxylic acid methyl ester | apoplon | deserpine | elserpine | hiserpia | raudixin | rau-sed | rauval | rauwasedin | reserpin | reserpine | (-)-reserpine | (−)-reserpine | rivasin | sandril | serpalan | serpanray | serpasil | serpate | serpine | serpivite

Organizations (59)

Research & Development (12)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (47)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (10)

Approved Indications (2)


 

Hypertension (approved 1955)

Psychotic Disorders (approved 1955)

Experimental Indications - Clinical Trial Phases 1-4 (9)


 

Amphetamine-Related Disorders (Phase 1)

Cardiovascular Diseases (Phase 3)

Cerebrovascular Disorders (Phase 3)

Cocaine-Related Disorders (Phase 2)

Heart Diseases (Phase 3)

Hypertension ()

Hypertension, Pulmonary (Phase 1)

Substance-Related Disorders (Phase 2)

Vascular Diseases (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 6
  • # of Trial Organizations: 12

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue